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A B S T R A C T
Background
Evidence from animal models and observational studies in humans has suggested that there is an inverse relationship between dietary
intake of omega 3 long-chain polyunsaturated fatty acids (LCPUFA) and risk of developing age-related macular degeneration (AMD)
or progression to advanced AMD.
Objectives
To review the evidence that increasing the levels of omega 3 LCPUFA in the diet (either by eating more foods rich in omega 3 or by
taking nutritional supplements) prevents AMD or slows the progression of AMD.
Search methods
We searchedCENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2015, Issue 1), OvidMEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to February
2015), EMBASE (January 1980 to February 2015), Latin American andCaribbean Health Sciences Literature Database (LILACS) (Jan-
uary 1982 to February 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov)
and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en).
We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 2
February 2015.
Selection criteria
We included randomised controlled trials (RCTs) where increased dietary intake of omega 3 LCPUFA was compared to placebo or no
intervention with the aim of preventing the development of AMD, or slowing its progression.
Data collection and analysis
Both authors independently selected studies, assessed them for risk of bias and extracted data. One author entered data into RevMan
5 and the other author checked the data entry. We conducted a meta-analysis for one primary outcome, progression of AMD, using a
ﬁxed-effect inverse variance model.
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Main results
We included two RCTs in this review, in which 2343 participants with AMD were randomised to receive either omega 3 fatty acid
supplements or a placebo. The trials, which had a low risk of bias, were conducted in the USA and France. Overall, there was no evidence
that people who took omega 3 fatty acid supplements were at decreased (or increased risk) of progression to advanced AMD (pooled
hazard ratio (HR) 0.96, 95% conﬁdence interval (CI) 0.84 to 1.10, high quality evidence). Similarly, people taking these supplements
were no more (or less) likely to lose 15 or more letters of visual acuity (USA study HR 0.96, 95% CI 0.84 to 1.10; French study at 36
months risk ratio (RR) 1.25, 95% CI 0.69 to 2.26, participants = 230). The number of adverse events was similar in the intervention
and placebo groups (USA study participants with one or more serious adverse event RR 1.00, 95% CI 0.91 to 1.09, participants =
2080; French study total adverse events RR 1.05, 95% CI 0.97 to 1.13, participants = 263).
Authors’ conclusions
This review found that omega 3 LCPUFA supplementation in people with AMD for periods up to ﬁve years does not reduce the risk
of progression to advanced AMD or the development of moderate to severe visual loss. No published randomised trials were identiﬁed
on dietary omega 3 fatty acids for primary prevention of AMD. Currently available evidence does not support increasing dietary intake
of omega 3 LCPUFA for the explicit purpose of preventing or slowing the progression of AMD.
P L A I N L A N G U A G E S U M M A R Y
Omega 3 fatty acids for preventing and slowing the progression of age-related macular degeneration
Review question
We asked the question whether increased dietary intake of omega 3 fatty acids prevented or slowed the progression of age-related
macular degeneration.
Background
Age-related macular degeneration (AMD) is an eye condition that affects the central area of the retina (light-sensitive tissue at the back
of the eye). AMD is associated with a loss of detailed vision and adversely affects tasks such as reading, driving and face recognition. In
the absence of a cure, there has been considerable interest in the role of modiﬁable risk factors to prevent or slow down the progression
of AMD. Evidence from population studies suggests that people who have a diet with relatively high levels of omega 3 fatty acids (such
as those derived from ﬁsh oils) are less likely to develop AMD.
Study characteristics
We searched for studies up to 2 February 2015. We identiﬁed two trials with a total of 2343 participants. The trials were conducted
in the USA and France and investigated the use of ﬁsh oil supplements in people with AMD who were at high risk of progressing to
advanced disease. We judged the studies to be at low risk of bias. One study was funded by government grants and the other study was
funded by the manufacturer of the dietary supplement.
Key results
These studies found that omega 3 supplementation for periods up to ﬁve years did not reduce the rate of progression to advanced AMD
or reduce signiﬁcant visual loss compared to a placebo. The incidence of adverse effects was similar in the intervention and placebo
groups.
Quality of the evidence
We judged the quality of the evidence on rate of progression to AMD to be high, and the quality of the evidence for other outcomes
to be moderate because the estimates were imprecise.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Omega 3 fatty acids compared to placebo for slowing the progression of age-related macular degeneration
Patient or population: people with AMD
Settings: community
Intervention: omega 3 fatty acids
Comparison: no omega 3 fatty acids (placebo)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No omega 3 fatty acids
(placebo)
Omega 3 fatty acids
Loss of 3 or more lines
of VA at 24 months
100 per 1000 114 per 1000
(53 to 245)
RR 1.14, 95% CI 0.53 to
2.45
236
(1 study)
⊕⊕⊕©
moderate1
Loss of 3 or more lines
of VA at 36 months
150 per 1000 187 per 1000
(104 to 339)
RR 1.25, 95% CI 0.69 to
2.26)
230
(1 study)
⊕⊕⊕©
moderate1
Incidence of CNV at 24
months
100 per 1000 106 per 1000
(47 to 240)
RR 1.06, 95% CI 0.47 to
2.40
224
(1 study)
⊕⊕⊕©
moderate1
Incidence of CNV at 36
months
150 per 1000 168 per 1000
(80 to 357)
RR 1.12, 95% CI 0.53 to
2.38
195
(1 study)
⊕⊕⊕©
moderate1
Progression of AMDover
5 years
300 per 1000 290 per 1000
(259 to 325)
HR 0.96
(0.84 to 1.1)
2343
(2 studies)
⊕⊕⊕⊕
high
Adverse effects 500 per 1000 505 per 1000
(470 to 545)
RR 1.01, 95% CI 0.94 to
1.09
2343
(2 studies)
⊕⊕⊕⊕
high
AREDS2 reported partic-
ipants with one or more
serious adverse events
(AE). NAT-2 reported to-
tal AE including treat-
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ment emergent and seri-
ous non-ocular events
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; HR: Hazard ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded for imprecision
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B A C K G R O U N D
Description of the condition
Age-related macular degeneration (AMD) is the most common
cause of blindness and visual impairment in developed countries,
accounting for over 50% of blind and partially sighted certiﬁca-
tions in the UK (Bunce 2010). Since the disease predominantly
affects individuals aged 55 years and over, its prevalence continues
to rise as the population is living longer. AMD is characterised by
degenerative changes within the macula, the central area of the
retina responsible for detailed vision and colour perception (Lim
2012). The early stage of AMD is associated with an accumulation
of small focal yellowish deposits (drusen) under the retinal pigment
epithelium, often with an associated pigmentary disturbance. At
this stage the patient is generally asymptomatic, however, as the
disease progresses large focal areas of retinal pigment epithelial cell
loss can occur, referred to as geographic atrophy, which leads to a
progressive worsening of central vision. In approximately 10% of
cases, an acute neovascular response arises under the retina, with
associated blurring or distortion of vision. If untreated, the result-
ing haemorrhagic and exudative pathology disrupts normal retinal
anatomy, eventually leading to the formation of a dense ﬁbrous
scar. When both eyes are affected, late AMD causes signiﬁcant
visual impairment, with difﬁculties in reading, driving and recog-
nising faces. It can, therefore, severely impact on vision-related
quality of life. The estimated prevalence of late AMD in popula-
tions of European ancestry is 1.4% at age 70 years, increasing to
5.6% at 80 and 20.1% at 90 years of age (Rudnicka 2012). In the
UK, the annual incidence of late AMD in the population aged 50
years and above is 4.1 per 1000 women and 2.6 per 1000 men
(Owen 2012).
There is currently no cure for AMD. Vascular endothelial growth
factor inhibitors that are injected directly into the vitreous hu-
mour of the eye can stabilise vision in neovascular AMD, however
no effective treatment is available for geographic atrophy. In the
absence of a cure, research has focused on preventing or slowing
the progression of AMD through the control of modiﬁable risk
factors, for example smoking or dietary modiﬁcation (including
the use of nutritional supplements).
Description of the intervention
This review considers the evidence for the role of omega 3 fatty
acids in the primary prevention and treatment of AMD. Fatty
acids are divided into three broad categories, saturated, monoun-
saturated and polyunsaturated. Although humans can synthesise
saturated and monounsaturated fats, they do not have the en-
zyme systems required to synthesise polyunsaturated fatty acids
and therefore dietary sources are essential. Long-chain polyun-
saturated fatty acids (LCPUFA) are classiﬁed according to their
chemical structure. They have a methyl group at one end of the
molecule and a carboxyl group at the other, separated by a chain
of 18 or more carbon atoms that contains two or more double
bonds. The n-3 variety of LCPUFA (designated ω-3 or omega 3)
has a double bond positioned three carbon atoms from the methyl
end of the molecule. Omega 3 LCPUFA are obtained principally
from dietary sources, however they can be synthesised from the
short-chain omega 3 fatty acid alpha linolenic acid, although en-
dogenous synthesis in humans is limited (Burdge 2002).
The omega 3 LCPUFA docosahexaenoic acid (DHA) is present
in high concentrations in retinal photoreceptors and is therefore
essential for visual function. Although a diet rich in oily ﬁsh, eggs,
nuts and particular vegetable oils provides a plentiful supply of
omega 3 fatty acids, there has been a great deal of interest in the
health beneﬁts of omega 3 supplementation, and commercially
available supplements in the form of oils and capsules are widely
available. Capsules typically contain a mixture of DHA and its
precursor eicosapentaenoic acid (EPA), often in combination with
antioxidant vitamins and minerals.
How the intervention might work
There is a plausible biological rationale for increasing omega 3
LCPUFA in AMD. DHA accounts for 50% to 60% of the total
fatty acid content of the outer segments of photoreceptors. The
constant turnover of outer segment membranes requires a contin-
uous dietary supply of DHA, or its precursors, and a deﬁciency
may predispose a person to the development of AMD. Omega
3 LCPUFA may also confer protection against the oxidative, in-
ﬂammatory and vasogenic processes that play a key role in the
pathogenesis of AMD (Kishan 2011; SanGiovanni 2005). In a
mouse model that develops a range of AMD-like retinal lesions,
progression of the disease was slowed and in some cases reversed in
a group of mice fed on a diet rich in DHA and EPA (Tuo 2009).
The protective effect of omega 3 LCPUFA was associated with a
reduction in pro-inﬂammatory mediators and an increase in the
levels of anti-inﬂammatory metabolites. An EPA rich diet has also
been shown to suppress experimental choroidal neovascularisation
(CNV) and CNV-related inﬂammatory molecules both in vitro
and in vivo (Koto 2007).
Epidemiological studies in humans have provided some evidence
that consumption of ﬁsh and foods rich in omega 3 LCPUFA
could reduce the risk of developing AMD (Chong 2009; Christen
2011; Hodge 2006; Tan 2009). Similarly, a nested cohort study
within the Age-Related Eye Disease Study (AREDS) found that
participants at moderate to high risk of progressing to late AMD
who reported the highest consumption of omega 3 LCPUFA were
30% less likely to develop geographic atrophy and neovascular
AMDwhen compared to those reporting the lowest consumption
(SanGiovanni 2009).
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Why it is important to do this review
The high prevalence of AMD and the limited availability of ef-
fective treatments for the majority of sufferers highlights the need
to search for new treatment strategies to prevent or slow the pro-
gression of the disease. There is signiﬁcant interest in the role of
diet and nutritional supplementation in AMD. There is evidence
that antioxidant vitamins (beta-carotene, vitamin C and vitamin
E) and zinc supplementation slow down the progression to ad-
vanced AMD (Evans 2012b), but there is no evidence to support
the use of these supplements in primary prevention (Evans 2012a).
Although observational studies have suggested a protective role
for omega 3 LCPUFA in the prevention and treatment of AMD,
these results may be confounded by other dietary or lifestyle fac-
tors. Therefore, a systematic review of randomised controlled tri-
als that examines the effect of increasing dietary intake of omega
3 LCPUFA in AMD was needed. The review considered evidence
for both atrophic and neovascular AMD.
O B J E C T I V E S
To review the evidence that increasing the levels of omega 3 LCP-
UFA in the diet (either by eating more foods rich in omega 3 or by
taking nutritional supplements) prevents or slows the progression
of AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) where increased
dietary intake of omega 3 fatty acids was compared to placebo or
no intervention.
Types of participants
People from the general population with or without AMD. The
deﬁnition of AMDwas taken as deﬁned by study investigators (for
example using a standardised grading scheme, or AMD leading to
a reduction in visual acuity).
Types of interventions
Any type and any dose of omega 3 fatty acids, either as ﬁsh oil
capsules or dietarymanipulation (for example increased consump-
tion of oily ﬁsh). The intervention could be delivered either as
monotherapy or in combination with other measures, where the
study design allowed for the effect of the omega 3 treatment to be
isolated. We imposed no restriction on the duration of treatment.
Types of outcome measures
Primary outcomes
We deﬁned the primary outcomes as follows:
• risk of developing incident AMD or new visual loss
attributed to AMD; and
• risk of progression of AMD in people previously diagnosed
with the disease.
Secondary outcomes
We deﬁned the secondary outcomes as follows:
• quality of life; and
• any adverse outcomes reported.
We assessed primary and secondary outcomes as reported by study
authors either in the short term (less than two years) or following
a longer-term intervention (more than two years).
We used the following deﬁnitions in the review.
• AMD: there are a number of internationally recognised
classiﬁcation systems that rely on photographic grading of
fundus images, e.g. Wisconsin Age-related Maculopathy Grading
System (Klein 1991) or the Age-Related Eye Disease Study
(AREDS) Classiﬁcation System (AREDS 1999) which
encompasses ﬁve categories of increasing severity from ’early’ to
’advanced’ AMD. However, study-speciﬁc deﬁnitions may also
be used, e.g. following ophthalmoscopic examination of the
retina or conﬁrmation from medical records of participant self
reporting of AMD.
• AMD progression: may be deﬁned by a change in severity
based on fundus appearance or progressive visual loss due to
AMD.
• Visual loss: any well-deﬁned outcome based on visual acuity
measured using a standardised measurement technique.
• Quality of life: any validated measurement scale which aims
to measure vision functioning or vision-speciﬁc quality of life.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes
and Vision Group Trials Register) (2015, Issue 1), Ovid MED-
LINE, Ovid MEDLINE In-Process and Other Non-Indexed Ci-
tations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January
1946 to February 2015), EMBASE (January 1980 to February
2015), Latin American and Caribbean Health Sciences Literature
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Database (LILACS) (January 1982 to February 2015), the IS-
RCTN registry (www.isrctn.com/editAdvancedSearch), Clinical-
Trials.gov (www.clinicaltrials.gov) and the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en).We did not use any date
or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 2 February 2015.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
LILACS (Appendix 4), mRCT (Appendix 5), ClinicalTrials.gov
(Appendix 6) and the ICTRP (Appendix 7).
Searching other resources
We reviewed the reference list of included studies to identify ad-
ditional trials for this review.
Data collection and analysis
Selection of studies
We screened the titles and abstracts of articles retrieved by the
searches independently. We obtained full-text copies of articles
that deﬁnitely or potentially met the inclusion criteria. We in-
dependently reviewed these and selected studies according to the
deﬁnitions in the Criteria for considering studies for this review.
We documented reasons for excluding studies at this stage and
resolved any disagreements by discussion.
Wewrote to authors of included studies to ask if theywere aware of
any published or unpublished studies on omega 3 acids in relation
to AMD.
Data extraction and management
We independently extracted data from eligible studies using a stan-
dardised form developed by the Cochrane Eyes and Vision Group.
We compared the results and resolved any discrepancies by discus-
sion. One author cut and pasted the data into Review Manager
5 (RevMan 2014) and the other checked that this was done cor-
rectly.
Assessment of risk of bias in included studies
We used the ’risk of bias’ assessment tool developed by Cochrane,
described in Chapter 8 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) to assess the quality of
included studies. The tool uses the following criteria.
• Sequence generation.
• Allocation concealment.
• Blinding (masking).
• Incomplete outcome data.
• Selective reporting.
• Other sources of bias.
We performed the ’risk of bias’ assessment independently and re-
solved any discrepancies by discussion.
Measures of treatment effect
In general for binary outcomes we used the risk ratio (RR). For the
analysis of progression to advanced AMD, the available data were
reported from Cox proportional hazard models and therefore for
this outcome the results were expressed as a hazard ratio.
Unit of analysis issues
The majority of studies in this area are parallel-group RCTs. Clus-
ter randomisation (where individuals are randomised in groups)
and cross-over trials are unlikely to be used to investigate the role
of omega 3 LCPUFA in AMD but will be considered in the future
if these studies become available.
We analysed the results by person since the individual is the unit
of randomisation (as the intervention is applied to the individual,
not the eye).
Dealing with missing data
The data included in this review represented an ’available case
analysis’. This makes the assumption that data are missing at ran-
dom. We recorded the amount of missing data and reasons for
exclusions and attrition, where available, and contacted investiga-
tors for clariﬁcation. We did not impute missing data.
Assessment of heterogeneity
We assessed heterogeneity by examining the forest plot, along with
the Chi2 test and the I2 statistic.
Assessment of reporting biases
There were insufﬁcient numbers of studies to carry out a funnel
plot analysis to investigate the relationship between treatment ef-
fect and study size.
Data synthesis
For data on progression of AMD, log hazard ratios and standard
errors were obtained from Cox proportional hazards regression
models. These results were combined using the generic inverse-
variance method and since only two trials were available for anal-
ysis, a ﬁxed-effect model was used.
Subgroup analysis and investigation of heterogeneity
Insufﬁcient data were available to perform any subgroup analyses.
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Sensitivity analysis
No sensitivity analysis was planned.
R E S U L T S
Description of studies
See: the Characteristics of included studies, Characteristics of
excluded studies and Characteristics of ongoing studies tables for
more information.
Results of the search
The electronic searches run in January 2012 yielded a total of 337
references. The Trials Search Co-ordinator scanned the search re-
sults, removed duplicates and removed 135 references which were
not relevant to the scope of the review. We screened the remaining
116 reports to identify potentially relevant studies. We obtained
full-text copies of four studies and excluded them after reading
the full reports (Feher 2005; Huang 2008; Johnson 2008; Scorolli
2002). We also excluded two studies after reading their unpub-
lished reports (NCT01258335; OPAL). We identiﬁed two on-
going studies (AREDS2; VITAL-AMD) and another completed
trial (ISRCTN98246501/NAT2)was awaiting publication. These
studies were to be assessed for inclusion in the review when data
became available.
An update search run in February 2015 identiﬁed a further 180
references (Figure 1). After de-duplication we screened 153 refer-
ences and discarded 146 as not being relevant to the scope of the
review. We obtained seven full-text reports for potential inclusion
in the review. After assessment we included three reports of two
trials (AREDS2; NAT2) and excluded three trials (Arnold 2013;
García Layana 2013; Ziegler 2013). We have identiﬁed an ongo-
ing trial (NCT02264938) and will assess this trial when results
become available. In the previous version of this review there were
three trials awaiting assessment, which would be included when
data became available. The VITAL-AMD trial has not yet been
completed and is still classed as ongoing. The study protocols for
AREDS2 and NAT2 have been removed from the review as the
results of these trials have now been published and incorporated
into the review as the two new included studies.
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Figure 1. Results from searching for studies for inclusion in the review.
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Included studies
Below is a summary of the two trials included in this review. See
Characteristics of included studies for detailed information on
individual trials.
Types of participants
Both trials included participants at high risk of developing ad-
vanced AMD; with either bilateral large drusen or large drusen
in one eye and advanced AMD in the fellow eye (AREDS2), or
early AMD in the study eye and CNV in the fellow eye (NAT2).
The mean age for people participating in the trials was 74 years.
On average, slightly more women than men were recruited (mean
percentage that were female 56%). People taking part in the tri-
als were either recruited from a single hospital clinic (NAT2), re-
cruited from specialist retinal clinics or were volunteers from the
general population (AREDS2).
Types of intervention
AREDS2 compared a daily dose of 650 mg EPA and 350 mg
DHA to placebo. All participants were additionally instructed to
take the original AREDS formula of antioxidant vitamins and
zinc (AREDS 1999) or were entered into a secondary randomisa-
tion to investigate the effects of variations of this formula. NAT2
compared 840 mg DHA and 270 mg EPA daily to placebo (olive
oil capsules). In AREDS2 the duration of supplementation was
ﬁve years and for NAT2 participants were supplemented for three
years.
Types of outcome measures
The main outcome measures for both trials were the development
of advanced AMD and loss of visual acuity corresponding to 15
letters or more from baseline. For AREDS2 advanced AMD was
deﬁned as central geographical atrophy (GA) or choroidal neo-
vascularisation (CNV) and was assessed by grading stereoscopic
fundus images using masked graders. For NAT2 the AMD out-
come was the occurrence of CNV in the study eye (conﬁrmed by
angiography). In both trials visual acuity was measured using a
standard ETDRS chart (15 letters corresponds to a loss of 3 lines
on the chart and is equivalent to a doubling of the visual angle).
Excluded studies
We excluded nine studies in total. Four randomised trials were
identiﬁedwithAMDendpoints (Arnold 2013; Feher 2005;García
Layana 2013; Scorolli 2002), however these were excluded since
the supplement used contained additional antioxidants and it was
not possible to isolate the effects of the omega 3 LCPUFA. One
study (Ziegler 2013) was a commentary. Two further trials (Huang
2008; Johnson 2008) investigated the bioavailability of omega 3
LCPUFA following supplementation with DHA and EPA with
or without the xanthophylls lutein and zeaxanthin. Another study
(NCT01258335) used multifocal electroretinograms to assess the
safety of high-dose omega 3 fatty acids, but did not report AMD
outcomes. Similarly for theOPALstudy,which investigated omega
3 LCPUFA supplements for cognitive impairment, eye data were
collected in a subset of participants but no AMD outcomes were
available.
Risk of bias in included studies
Figure 2 and Figure 3 summarise the ’risk of bias’ assessment.
Overall, we considered the trials to be at low risk of bias for the
main types of bias.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
AREDS2 randomised participants using a random block design,
which was conducted by the AREDS2 Co-ordinating Centre.
NAT2 used a computer generated random sequence that was car-
ried out by an independent auditor.
Masking
InAREDS2 andNAT2participants and investigatorsweremasked
to the treatment assignment during the study. In AREDS2 the
study supplements were identical in appearance, size, smell and
taste to their placebo counterparts. InNAT2 the placebo contained
olive oil and had the same appearance and weight as the active
treatment.
Incomplete outcome data
In AREDS2 missing outcome data were balanced in numbers
across the intervention and placebo groups with similar reasons
for missing data. NAT2 used a per protocol analysis. The main
reason for protocol deviation was premature withdrawal, which
occurred at a similar rate in the DHA and placebo groups. Other
protocol deviations included ‘non-compliance with study medica-
tion or use of non-permitted medication’. Two hundred and sixty
three of the original 300 participants randomised were included
in the analysis.
Selective reporting
For both trials all outcomes that are of interest in this review were
reported in the pre-speciﬁed way.
Effects of interventions
See: Summary of findings for the main comparison Omega 3
fatty acids compared to placebo for slowing the progression of
age-related macular degeneration
Prevention of AMD
We did not identify any trials of omega 3 fatty acids in people
without AMD.
Slowing the progression of AMD
New visual loss attributed to AMD
Visual acuity data was reported by both trials as a dichotomous
outcome (loss of 3 or more lines of visual acuity).
NAT2 reported visual acuity outcomes at 12, 24 and 36 months.
At each of these time points there was no evidence of a protective
effect of omega 3 fatty acids, but the estimates were uncertain with
wide conﬁdence intervals (CIs): at 12 months, RR 6.57, 95% CI
0.82 to 52.65, participants = 254; at 24 months, RR 1.14, 95%
CI 0.53 to 2.45, participants = 236; and at 36 months, RR 1.25,
95% CI 0.69 to 2.26, participants = 230.
AREDS2 reported visual acuity outcomes at 60 months (adjusted
for baseline AMD status) as a hazard ratio (HR). Again there was
no little or no evidence of an effect: HR 0.96 (95% CI 0.84 to
1.10, participants = 2080).
Progression of AMD
Both of the included trials reported data on progression of AMD
as time to occurrence of advanced AMD. This was deﬁned as
either GA or CNV in either eye in AREDS2 and CNV in the
study eye in NAT2. The pooled analysis included 2343 people
who experienced 1071 advanced AMD events. The results were
reasonably consistent and provided no evidence of any beneﬁcial
effect of omega 3 supplementation, pooled HR 0.96 (95% CI
0.84 to 1.10) (Figure 4).
Figure 4. Forest plot of comparison (Analysis 1.1): 1 Omega 3 fatty acids versus control, outcome: 1.10
Progression of AMD.
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NAT2 reported the incidence of CNV at 12, 24 and 36 months.
At each of these time points there was no evidence of a protective
effect of omega 3 fatty acids, but the estimates were uncertain
with wide CIs (at 12 months, RR 1.12, 95% CI 0.54 to 2.34,
participants = 263; at 24 months, RR 1.06, 95% CI 0.47 to 2.40,
participants = 224; and at 36 months, RR 1.12, 95% CI 0.53 to
2.38, participants = 195).
Quality of life
Neither of the trials reported data on quality of life.
Adverse effects
AREDS2 reported ’serious’ adverse events only (Table 1). The
number of events was similar in the intervention and placebo
groups (RR 1.00, 95% CI 0.91 to 1.09, participants = 2080). In
NAT2, the frequency of adverse events similarly did not differ
between the two arms of the study (RR 1.05, 95% CI 0.97 to
1.13, participants = 263). Five participants (3.7%) in the omega
3 group and two participants (1.6%) in the placebo group experi-
enced adverse reactions that were considered by the authors to be
potentially treatment-related (including gastrointestinal disorders,
allergic dermatitis and breath odour).
D I S C U S S I O N
Summary of main results
This review provides evidence that dietary omega 3 LCPUFA sup-
plementation does not slow the progression of AMD or reduce
the risk of developing moderate to severe visual loss. The review
included data from two RCTs that randomised 2343 individuals
with AMD to receive either omega 3 fatty acid supplements or
placebo. Duration of supplementation ranged from three to ﬁve
years. No statistically signiﬁcant effect on incidence of advanced
AMD, progression to advanced AMD or on moderate to severe
visual loss were observed. The number of adverse events was sim-
ilar between the intervention and placebo groups.
Overall completeness and applicability of
evidence
The results from both trials were reasonably consistent although
the main evidence for a null effect comes from the AREDS2 trial.
This was a large well-conducted randomised study and therefore
any potential biases would have been minimised. There are still
some unanswered questions, for example we do not know whether
the effects of the intervention differ in different populations (for
example different ethnicities, nutritional states) or stage of the dis-
ease, and whether the composition (EPA:DHA ratio) or source of
omega 3 PUFA (oily ﬁsh versus ﬁsh oil supplements) is important.
We did not identify any trials of supplementation in the general
population, that is we do not know whether omega 3 supplemen-
tation prevents AMD.
Quality of the evidence
Overall we judged the quality of the evidence to be moderate or
high. We downgraded some outcomes for imprecision.
Potential biases in the review process
We followed standard procedures expected by The Cochrane Col-
laboration.
Agreements and disagreements with other
studies or reviews
A systematic review of the effect of dietary omega 3 fatty acids on
progressionofAMD, including only oneRCTandone prospective
cohort study, found inconclusive evidence for a beneﬁcial effect
(Hodge 2007). Although two systematic reviews (Chong 2009;
Hodge 2006) of omega 3 fatty acids for primary prevention of
AMD found some evidence based on observational studies that
consumption of ﬁsh and foods rich in omega 3 LCPUFA was as-
sociated with a lower risk of AMD, the authors of both reviews
concluded that the lack of evidence from RCTs precluded recom-
mending increasing dietary intake omega 3 fatty acids speciﬁcally
for AMD prevention.
Omega 3 fatty acids have been extensively studied for their po-
tential health beneﬁts. However, there is continuing controversy
regarding their effectiveness. For example, a Cochrane review
(Hooper 2004) which included data from 48 RCTs and 41 cohort
studies concluded that dietary or supplemental omega 3 fats did
not alter total mortality, combined cardiovascular events or can-
cers in people with, or at high risk of, cardiovascular disease or in
the general population. Randomisation to omega 3 fats increased
the risk of dropping out due to side effects (RR 1.62, 95%CI 1.10
to 2.40). The most common side effects included a bad or ﬁshy
taste or belching (RR 3.63, 95% CI 1.97 to 6.67) and nausea (RR
3.88, 95% CI 1.42 to 10.58).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although observational studies have shown that the consumption
of dietary omega 3 fatty acids or increased ﬁsh intake may confer
protection against age-related macular degeneration (AMD) and
reduce the risk of progression to advanced AMD, there is no ev-
idence from RCTs to support increasing omega 3 intake for the
explicit purpose of preventing or slowing the progression of AMD.
Implications for research
The lack of an effective treatment for the majority of individuals
with AMD represents a major public health problem. Reducing
the risk of developing AMD or slowing its progression through
dietarymodiﬁcation remains an important area for future research.
In nutritional cohort studies, residual confounding from other
dietary or lifestyle variables is always a problem. Such confounding
can be avoided in RCTs. The trials reported in this review failed to
demonstrate any protective effects of omega 3 supplementation in
peoplewithAMDwhowere at high risk of progressing to advanced
disease. However, there are still some unanswered questions in
terms of target population and the composition and timing of
the intervention. RCTs are expensive to conduct and a more cost-
effective approach would be to include AMD outcomes in large
trials of other morbidities for example cancer or cardiovascular
disease. One such trial, VITAL-AMD, is ongoing.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
AREDS2
Methods Parallel group RCT, 2 x 2 factorial design
Both eyes included in the trial, both eyes received same treatment, adjustment made for
within person correlation
Participants Country: USA
Setting: community
Number of participants: 2080, 55% women
Average age: 74 years
Age range: 50 to 85 years
Inclusion criteria:
• bilateral large drusen or large drusen in 1 eye and advanced AMD in the fellow eye
• consent to follow-up of at least 5 years
• took at least 75% of the run-in supplements and agreed to stop the use of other
supplements containing lutein, zeaxanthin, DHA, EPA, vitamin C, vitamin E, beta-
carotene, zinc, or copper
Exclusion criteria:
• other ocular diseases such as high myopia, glaucoma, clinically signiﬁcant diabetic
retinopathy (10 or more microaneurysms or retinal haemorrhages), and other diseases
that might confound the assessment of the ocular outcome measurements
• eyes that had undergone intraocular (apart from cataract) surgeries
• systemic diseases, including oxalate kidney stones, Wilson disease,
haemochromatosis, lung cancer, or other diseases associated with poor 5-year survival
Approximately 90% of participants were taking an additional multivitamin supplement
Interventions • Omega 3 fatty acids (n = 1068 people, 1753 eyes)
• Placebo (n = 1012 people, 1695 eyes)
Omega 3 fatty acids were DHA (350 mg per day) and EPA (650 mg per day). Compo-
sition of placebo not speciﬁed
All participants were asked to take the original AREDS formulation (vitamin C 500 mg,
vitamin E 400 IU, beta-carotene 15 mg, zinc oxide 80 mg, cupric oxide 2 mg). Those
who agreed to take AREDS and consented to a second randomisation were assigned as
follows
• Original AREDS formula: omega 3 fatty acids group n = 147 (13.8%); placebo
group n = 168 (16.6%)
• No beta-carotene: omega 3 fatty acids group n = 231 (21.6%); placebo group n =
201 (19.9%)
• Low-dose zinc (25 mg): omega 3 fatty acids group n = 179 (16.8%); placebo
group n = 184 (18.2%)
• No beta-carotene and low-dose zinc: omega 3 fatty acids group n = 201 (18.8%);
placebo group n = 190 (18.8%)
The participantswhodidnot agree to a secondary randomisation largely took theAREDS
formula: omega 3 fatty acids group n = 305 (28.6%); placebo group n = 265 (26.2%)
Participants who were current smokers or former smokers who had stopped smoking
within the year before enrolment were randomly assigned to 1 of the 2 arms without
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AREDS2 (Continued)
beta-carotene
Duration: 5 years
Outcomes Primary outcome:
• Development of advanced AMD, deﬁned as central geographic atrophy or retinal
features of choroidal neovascularization detected on central grading of the stereoscopic
fundus photographs or a history of treatment for advanced AMD after study enrolment
Secondary outcomes:
• Progression to moderate vision loss (3 lines) from baseline or treatment for
choroidal neovascularisation
• Serious adverse events
• Mortality
Follow-up: annually
Dates participants recruited 10/2006 to 09/2008
Declaration of interest Yes - reported in paper. Including patent for AREDS formula
Sources of funding This study was supported by the intramural program funds and contracts from the Na-
tional Eye Institute (NEI), National Institutes of Health (NIH), Department of Health
and Human Services, Bethesda, Maryland (contract HHS-N-260-2005-00007-C; ADB
contract N01-EY-5-0007). Funds were contributed by the following NIH institutes:
Ofﬁce of Dietary Supplements; National Center for Complementary and Alternative
Medicine; National Institute on Aging; National Heart, Lung, and Blood Institute; and
National Institute of Neurological Disorders and Stroke. The study medications and raw
materials were provided by Alcon, Bausch & Lomb, DSM, and Pﬁzer
Notes In the primary randomisation 84% of participants took 75% of the study medications
http://clinicaltrials.gov/show/NCT00345176
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A random block design was implemented us-
ing the AREDS2 Advantage Electronic Data
Capture system by the AREDS2 Coordi-
nating Center (The EMMES Corporation,
Rockville, MD) and stratified by clinical cen-
ter and AMD status (large drusen both eyes
or large drusen in 1 eye and advanced AMD
in the fellow eye) to ensure approximate bal-
ance across centers over time.” Page 2285 of
protocol paper
Allocation concealment (selection bias) Low risk Placebo-controlled study
“Participants and study personnel were
masked to treatment assignment in both ran-
domizations.”
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AREDS2 (Continued)
Page E2 of main study report
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk “Participants and study personnel were
masked to treatment assignment in both ran-
domizations.” Page E2 of main study report
Blinding of participants and personnel
(performance bias)
Progression of AMD
Low risk “Participants and study personnel were
masked to treatment assignment in both ran-
domizations.” Page E2 of main study report
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk “Participants and study personnel were
masked to treatment assignment in both ran-
domizations.”
Page E2 of main study report
Blinding of outcome assessment (detection
bias)
Progression of AMD
Low risk “Participants and study personnel were
masked to treatment assignment in both ran-
domizations.”
Page E2 of main study report
CNV was determined by masked readers
from stereoscopic fundus photographs
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up was high and balanced across
groups
• DHA/EPA: 1062/1068 (99.4%)
• Placebo: 1007/1012 (99.5%)
Selective reporting (reporting bias) Low risk Not detected
NAT2
Methods Parallel-group RCT
One eye only included, study eye was selected on the basis of early AMDwith neovascular
AMD (CNV) in the fellow eye
Participants Country: France
Setting: community
Number of participants: 300, 65% women
Average age: 74 years
Age range: 55 to 85 years
Inclusion criteria:
• bilateral large drusen or large drusen in 1 eye and CNV in the fellow eye (grading
performed using a validated classiﬁcation grid http://www.ncbi.nlm.nih.gov/pubmed/
16988630)
• visual acuity better than 0.4 logarithm of minimum angle of resolution units in
the study eye
• patients likely to attend follow-up visits during the study period and consent to
follow-up of at least 5 years
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NAT2 (Continued)
Exclusion criteria:
• CNV in both eyes or no CNV in either eye
• wide central subfoveal atrophy of the study eye
• progressive ocular diseases (severe glaucoma or other severe retinopathy)
• major corneal or lens opacities precluding retinal evaluation
• serious systemic disease (cancer, stroke, etc.) preventing long-term participation
• known allergy to the substances used in the study (ﬁsh oil, ﬂuorescein,
indocyanine green)
• anticoagulant therapy (prohibited medication) or bleeding tendency
• current or recent treatment (< 6 months) with nutritional supplements (oral
supplement containing long-chain omega 3 fatty acids or alpha tocopherol acetate)
• any concomitant nutritional supplement
• participation in a clinical trial within the previous 30 days
• history of drug use or excessive use of medication
• patients likely to be lost to follow-up or unlikely to comply with the study
protocol
• monocular patients for reasons other than AMD
• patients not covered by the French National Health system or wards of the court
Interventions • Omega 3 fatty acid (n = 150 people)
• Placebo (n = 150 people)
Omega 3 fatty acids were 3 ﬁsh oil capsules, each capsule contained: DHA (280 mg),
EPA (90mg) and vitamin E (2mg) (Reti-Nat, provided by Bausch&Lomb,Montpellier,
France)
Placebo contained 602 mg of olive oil
Duration: 3 years
Outcomes Primary outcome:
• time to occurrence of CNV in the study eye
Secondary outcome:
• percentage of patients in whom CNV developed
• changes in visual acuity from baseline (logMAR)
• visual acuity decrease of 15 letters on the Early Treatment Diabetic Retinopathy
Study (ETDRS) chart
• drusen burden and progression, based on automatic detection of their number,
size, and area on fundus photography
• changes in red blood cell membrane (RBCM) EPA plus DHA levels
• lens opacity
• blood lipids including fasting plasma lipoprotein proﬁle
• signs of intolerance related to ﬁsh oil consumption
• occurrence of systemic adverse events
Follow-up: annually
Dates participants recruited 12/2003 to 10/2005
Declaration of interest Eric H Souied: Consultant and lecturer-Laboratoire Bausch & Lomb Chauvin
Pascale Benlian: Financial support and lecturer-Laboratoire Bausch & Lomb Chauvin
Cécile Delcourt: Consultant and ﬁnancial support-Laboratoire Bausch & Lomb Chau-
vin; Consultant and ﬁnancial support-Laboratoires Théa; Consultant-Novartis
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NAT2 (Continued)
Sources of funding Sponsored by Laboratoire Bausch & Lomb Chauvin, Montpellier
Notes http://www.controlled-trials.com/ISRCTN98246501
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “QL-Ranclin software (Qualilab, Olivet,
France) was used to generate the randomiza-
tion list before enrolment.”
Souied et al 2013 p3
Allocation concealment (selection bias) Low risk “The patients and the study personnel both
were blinded to the treatment assignment.”
Souied et al 2013 p3
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Not well reported. However, Qualilab pro-
vides an independent trial auditing service
(not clear if this was the case here). No in-
formation provided regarding the outcome
assessors (?study personnel), however it is
likely that they remained masked as to the
allocation
Blinding of participants and personnel
(performance bias)
Progression of AMD
Low risk Not well reported. However, Qualilab pro-
vides an independent trial auditing service
(not clear if this was the case here). No in-
formation provided regarding the outcome
assessors (?study personal), however it is
likely that they remained masked as to the
allocation
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Not well reported. However, Qualilab pro-
vides an independent trial auditing service
(not clear if this was the case here). No in-
formation provided regarding the outcome
assessors (?study personal), however it is
likely that they remained masked as to the
allocation
Blinding of outcome assessment (detection
bias)
Progression of AMD
Low risk Not well reported. However, Qualilab pro-
vides an independent trial auditing service
(not clear if this was the case here). No in-
formation provided regarding the outcome
assessors (?study personal), however it is
likely that they remained masked as to the
allocation
22Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NAT2 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Used a per protocol analysis. Main reason
for protocol deviation was premature with-
drawal which occurred at a similar rate in
DHA and placebo groups. Other protocol
deviations included ‘non-compliance with
study medication or use of non-permit-
ted medication’; 263 of the original 300
patients randomised were included in the
analysis
Selective reporting (reporting bias) Low risk All pre-speciﬁed primary outcomes re-
ported. All secondary outcomes (with the
exception of mERG listed in trial protocol)
were reported
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arnold 2013 Omega 3 fatty acids combined with carotenoids. Not able to isolate the effect of omega 3 treatment
Feher 2005 A total of 106 participants with early AMD were randomised to receive a supplement containing acetyl-L-
carnitine, co-enzyme Q10 and omega 3 fatty acids or placebo for 12 months. The outcomes measured were
change in visual ﬁeld defect, visual acuity and AMD grading from baseline. This study was excluded since it
was not possible to isolate the speciﬁc effects of the omega 3 treatment
García Layana 2013 Omega 3 fatty acids combined with carotenoids. Not able to isolate the effect of omega 3 treatment
Huang 2008 This was a bioavailability study for the AREDS2 trial; 40 participants with AMD were randomly assigned to
receive lutein and zeaxanthin, DHA/EPA or placebo for 6 months. Serum levels of lutein, zeaxanthin, DHA
and EPA were measured in addition to macular pigment optical density. This study was excluded since no
data on AMD outcomes were reported
Johnson 2008 A total of 49 participants recruited from the general population were randomly assigned to placebo, lutein or
lutein plus DHA. Supplements were taken for 4 months. The outcomes were serum levels of lutein and DHA
and macular pigment optical density. This study was excluded since no data on AMD outcomes were reported
NCT01258335 The ‘Short Term Ocular Safety Assessment of High Dose Omega 3 Supplementation for Age-Related Mac-
ular Degeneration’ study was a RCT that used multifocal ERGs to establish the safety of omega LCPUFA
supplements. The trialists conﬁrmed that no AMD outcomes were collected and safety data or quality of life
data were not available
OPAL The ‘Older People And n-3 Long-chain polyunsaturated fatty acids’ study was a randomised trial to assess the
effects of oral supplementation with omega 3 LCPUFAs on cognitive decline. The effect of the supplement
on visual function was also investigated in a sub-set of participants by assessing rod photoreceptor response to
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(Continued)
light and visual-cortical integration. Trialists conﬁrmed that no AMD outcomes were collected and the study
was therefore excluded. Reporting of minor adverse events was similar between trial arms
Scorolli 2002 A total of 35 participants with bilateral late AMD were randomly assigned to either receive (20 patients) or
not receive (15 patients) a supplement containing vitamin E and polyunsaturated fatty acid for 60 days after
photodynamic therapy. The outcomes measured were visual acuity (logMAR) and retinal metabolic function.
This study was excluded since it was not possible to isolate the speciﬁc effects of the omega 3 treatment
Ziegler 2013 Commentary
AMD: age-related macular degeneration
DHA: docosahexaenoic acid
EPA: eicosapentaenoic acid
ERG: electroretinogram
LCPUFA: long-chain polyunsaturated fatty acids
logMAR: logarithm of the Minimum Angle of Resolution
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT02264938
Trial name or title Drusen morphology changes in non-exudative age-related degeneration after oral antioxidants supplementa-
tion
Methods Randomised unmasked controlled trial of oral supplementation with a preparation containing antioxidants
and omega 3 fatty acids for one year compared to no supplement (observation)
Participants People with AREDS category 2 and 3 AMD
Interventions Daily dose of a AREDS-like supplement containing lutein (12 mg), zeaxanthin (2 mg), astaxanthin (8 mg),
omega 3 fatty acids (DHA 540 mg and EPA 360 mg), vitamin C (40 mg), vitamin E (20 mg), zinc (16 mg)
and copper (2 mg)
Outcomes Changes in drusen morphology (volume and area) measured automatically with Topcon 3D OCT-2000 at
baseline and 12 months
Starting date January 2013. Final data collection date for primary outcome measure July 2014
Contact information See ClinicalTrials.gov website for details
Notes http://ClinicalTrials.gov/show/NCT02264938
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VITAL-AMD
Trial name or title Ancillary AMD study to the vitamin D and omega 3 trial (VITAL)
Methods VITAL is a randomised, double-masked, placebo-controlled, 2 x 2 factorial trial of vitamin D and marine
omega 3 fatty acid (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) supplements in the
primary prevention of cancer and cardiovascular disease
Participants The study planned to enrol 20,000 male or female participants aged 50 years without cancer or cardiovascular
disease at baseline
Interventions The intervention groups received oral supplementation with vitamin D (cholecalciferol; 2000 IU) or marine
omega 3 fatty acid (EPA + DHA, 1 g/d) supplements. Control groups received an inactive placebo
Outcomes The AMD endpoint will be based on medical record-conﬁrmed self reports and retinal photographs
Starting date July 2010
End date: June 2016
Contact information See ClinicalTrials.gov website for details
Notes http://clinicaltrials.gov/ct2/show/NCT01169259
AMD: age-related macular degeneration
LCPUFA: long-chain polyunsaturated fatty acids
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D A T A A N D A N A L Y S E S
Comparison 1. Omega 3 fatty acids versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Progression of AMD 2 Hazard Ratio (Fixed, 95% CI) 0.96 [0.84, 1.10]
Analysis 1.1. Comparison 1 Omega 3 fatty acids versus control, Outcome 1 Progression of AMD.
Review: Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration
Comparison: 1 Omega 3 fatty acids versus control
Outcome: 1 Progression of AMD
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS2 (1) -0.0305 (0.069828) 92.5 % 0.97 [ 0.85, 1.11 ]
NAT2 (2) -0.1165 (0.2456) 7.5 % 0.89 [ 0.55, 1.44 ]
Total (95% CI) 100.0 % 0.96 [ 0.84, 1.10 ]
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours omega-3 Favours placebo
(1) Progression over 5 years; unit of analysis eye, adjusted for within person correlation.
(2) Incidence of CNV in fellow eye over 3 years; unit of analysis study eye, one per person; adjusted for age, smoking and stage of maculopathy.
A D D I T I O N A L T A B L E S
Table 1. Adverse effects
Adverse effects Omega 3
N (%)
Placebo
N (%)
AREDS 2
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Table 1. Adverse effects (Continued)
Total number of participants N = 1068 N = 1012
Participants with ≥ 1 adverse event
· Cardiac disorders
· Gastrointestinal disorders
· Infections
· Neoplasms
· Nervous system disorders
· Respiratory and chest disorders
505 (47.3)
119 (11.1)
58 (5.4)
103 (9.6)
83 (7.8)
72 (6.7)
37 (3.5)
479 (47.3)
96 (9.5)
76 (7.5)
90 (8.9)
80 (7.9)
66 (6.5)
44 (4.3)
NAT-2
Total number of participants N = 134 N = 129
Total adverse events
· Treatment emergent adverse events*
· Ocular
· Serious non-ocular
125 (83.3)
5 (4.7)
88 (58.4)
31 (23.1)
115 (77.7)
2 (1.6)
74 (50.0)
30 (23.6)
* As deﬁned by the study authors (including gastrointestinal disorders, allergic dermatitis and breath odour)
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration
#3 MeSH descriptor Retinal Neovascularization
#4 MeSH descriptor Choroidal Neovascularization
#5 MeSH descriptor Macula Lutea
#6 macula* near lutea*
#7 (macula* or retina* or choroid*) near/4 degenerat*
#8 (macula* or retina* or choroid*) near/4 neovascul*
#9 maculopath*
#10 AMD or ARMD or CNV
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
#12 MeSH descriptor Fatty Acids, Omega-3
#13 fatty near/2 acid*
#14 omega 3
#15 polyunsaturated
#16 LCPUFA* or PUFA*
#17 docosahexaenoic or DHA*
#18 eicosapentaenoic or EPA*
#19 (#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)
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#20 (#11 AND #19)
Appendix 2. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp retinal degeneration/
14. retinal neovascularization/
15. choroidal neovascularization/
16. exp macula lutea/
17. maculopath$.tw.
18. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
19. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
20. (AMD or ARMD or CNV).tw.
21. or/13-20
22. Fatty Acids, Omega-3/
23. (fatty adj2 acid$).tw.
24. omega 3.tw.
25. polyunsaturated.tw.
26. (LCPUFA$ or PUFA$).tw.
27. (docosahexaenoic or DHA$).tw.
28. (eicosapentaenoic or EPA$).tw.
29. or/22-28
30. 21 and 29
31. 12 and 30
The search ﬁlter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
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14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina degeneration/
34. retina neovascularization/
35. subretinal neovascularization/
36. exp retina macula lutea/
37. maculopath$.tw.
38. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
39. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
40. (AMD or ARMD or CNV).tw.
41. or/33-40
42. omega 3 fatty acid/
43. (fatty adj2 acid$).tw.
44. omega 3.tw.
45. polyunsaturated.tw.
46. (LCPUFA$ or PUFA$).tw.
47. docosahexaenoic acid/
48. (docosahexaenoic or DHA$).tw.
49. icosapentaenoic acid/
50. (eicosapentaenoic or EPA$).tw.
51. or/42-50
52. 41 and 51
53. 32 and 52
Appendix 4. LILACS search strategy
macular degenerat$ or AMD or AMRD or CNV and omega or fatty acid or polyunsaturated or docosahexaenoic or eicosapentaenoic
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Appendix 5. metaRegister of Controlled Trials search strategy
(macular degeneration) AND omega
Appendix 6. ClinicalTrials.gov search strategy
(Macular Degeneration) AND Omega 3
Appendix 7. ICTRP search strategy
(Macular Degeneration) AND Omega 3
WH A T ’ S N E W
Last assessed as up-to-date: 2 February 2015.
Date Event Description
15 April 2015 Amended Table 1 reformatted
H I S T O R Y
Protocol ﬁrst published: Issue 8, 2012
Review ﬁrst published: Issue 11, 2012
Date Event Description
10 April 2015 Amended Amended conﬁdence interval in abstract
11 March 2015 New citation required and conclusions have changed Issue 4, 2015: Two trials were identiﬁed that met the in-
clusion criteria (AREDS2; NAT2)
11 March 2015 New search has been performed Issue 4, 2015: Electronic searches updated
30Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
JL assessed studies for inclusion and exclusion, assessed risk of bias, extracted data, entered data and authored the ﬁrst draft of the
review
JE assessed studies for inclusion and exclusion, assessed risk of bias, extracted data, entered data reviewed and commented on the text
of the review
D E C L A R A T I O N S O F I N T E R E S T
JL: none known
JE: none known
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
• Richard Wormald, Co-ordinating Editor for the Cochrane Eyes and Vision Group (CEVG) acknowledges ﬁnancial support for
his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to
Moorﬁelds Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre
for Ophthalmology.
• The NIHR also funds the CEVG Editorial Base in London.
The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS, or the Department of
Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
None
N O T E S
None
31Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Disease Progression; Fatty Acids, Omega-3 [∗therapeutic use]; Macular Degeneration [∗prevention & control]
MeSH check words
Humans
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